Clarity AI’s Sustainability Data and Capabilities Will Support BlackRock’s Enterprise SFDR Reporting
1.6.2022 11:00:00 EEST | Business Wire | Press release
Clarity AI, the global sustainability tech platform, announced today that their sustainability data, integrated into BlackRock’s Aladdin platform, is being utilized in preparation for BlackRock’s enterprise reporting for the Sustainable Finance Disclosure Regulation (SFDR) framework. BlackRock will leverage Clarity AI capabilities, data and expertise to facilitate efficient and accurate reporting on Principal Adverse Impact (PAI) indicators. PAI indicators are a set of specific ESG metrics mandated by the European Union as part of SFDR, which imposes granular sustainability disclosure obligations for asset managers and other financial market participants.
“We are thrilled to deepen our client relationship with BlackRock,” said Rebeca Minguela, Founder & CEO of Clarity AI. “As part of our comprehensive sustainability tech kit, we are uniquely positioned in the market to deliver everything required for regulatory reporting, including SFDR, EU Taxonomy, UK Taxonomy, TCFD and MiFID II. Financial market participants of any size can leverage these capabilities via custom, easy integrations or our off-the-shelf web app.”
Clarity AI’s market-leading SFDR coverage encompasses more than 49,000 companies, and its capabilities allow for portfolio aggregation and multi-asset look-through to more than 220,000 funds, including ETFs. All data is fully granular, which allows for better understanding of underlying calculations for each SFDR PAI. Should they choose to, financial market participants will be able to access these capabilities and data within their own configuration of Aladdin and leverage them as an input according to their own portfolio and reporting needs.
"Deepening our partnership with Clarity AI is an exciting step forward for BlackRock and will provide us the ability to offer Aladdin users enterprise level reporting for SFDR,” said Stéphane Lapiquonne, Managing Director at BlackRock and Head of Sustainability for Europe, Middle East and Africa. “The depth and transparency behind Clarity AI data can help Aladdin users better understand exposures to the PAI metrics across their portfolios.”
About Clarity AI
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. As of May 2022, Clarity AI’s platform analyzes more than 49,000 companies, 220,000 funds, 198 countries and 188 local governments, and delivers data and analytics for investing, corporate research and reporting. Clarity AI has offices in North America, Europe and the Middle East, and its client network manages tens of trillions in assets under management. Clarity AI’s minority investors include, but are not limited to, Deutsche Börse, BlackRock, and SoftBank. clarity.ai
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005583/en/
Contact information
Media Contact
Edelman
Julia Wright
clarityAI@edelmansmithfield.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom